114 related articles for article (PubMed ID: 27287328)
1. Inhibitory Effect of Apigenin on Losartan Metabolism and CYP2C9 Activity in vitro.
Wang Z; Gong Y; Zeng DL; Chen LG; Lin GT; Huang CK; Sun W; Chen MC; Hu GX; Chen RJ
Pharmacology; 2016; 98(3-4):183-9. PubMed ID: 27287328
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes.
Wang Z; Sun W; Huang CK; Wang L; Xia MM; Cui X; Hu GX; Wang ZS
Drug Dev Ind Pharm; 2015 Apr; 41(4):613-6. PubMed ID: 24517573
[TBL] [Abstract][Full Text] [Related]
3. The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.
Mukai Y; Senda A; Toda T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):408-14. PubMed ID: 26551762
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes.
Senda A; Mukai Y; Hayakawa T; Kato Y; Eliasson E; Rane A; Toda T; Inotsume N
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):239-245. PubMed ID: 28374982
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of calf thymus DNA on metabolism activity of CYP450 enzyme in human liver microsomes.
Yang S; Qiu Z; Zhang Q; Chen J; Chen X
Drug Metab Pharmacokinet; 2014; 29(6):475-81. PubMed ID: 25030415
[TBL] [Abstract][Full Text] [Related]
6. Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9.
Wang R; Zhang H; Wang Y; Yu X; Yuan Y
J Ethnopharmacol; 2016 Mar; 180():87-96. PubMed ID: 26806573
[TBL] [Abstract][Full Text] [Related]
7. Effects of dibutyl phthalate and di(2-ethylhexyl) phthalate with their metabolites on CYP2C9*1 and CYP2C19*1 activities in vitro.
Chen B; Hu X; Zhen X; Hu GX
J Pharm Biomed Anal; 2018 Oct; 160():195-201. PubMed ID: 30099291
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo drug-drug interaction of losartan and glimepiride in rats and its possible mechanism.
Chen SZ; Pan PP; Wang SH; Luo J; Hu GX; Xu SS; Zhang L; Yu YF
Pharmacology; 2015; 95(3-4):133-8. PubMed ID: 25823852
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory Effect of Apigenin on Pharmacokinetics of Venlafaxine in vivo and in vitro.
Zhan YY; Liang BQ; Gu EM; Hu XX; Lin D; Hu GX; Zheng ZQ
Pharmacology; 2015; 96(3-4):118-23. PubMed ID: 26202346
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of CYP1A2, CYP2C9, and CYP2D6 by pterostilbene in human liver microsomes.
Albassam AA; Ahad A; Alsultan A; Yusufoglu HS; Foudah AI; Al-Jenoobi FI
Pharmazie; 2021 Apr; 76(4):155-158. PubMed ID: 33849700
[TBL] [Abstract][Full Text] [Related]
11. Screening of Drug Metabolizing Enzymes for the Ginsenoside Compound K In Vitro: An Efficient Anti-Cancer Substance Originating from Panax Ginseng.
Xiao J; Chen D; Lin XX; Peng SF; Xiao MF; Huang WH; Wang YC; Peng JB; Zhang W; Ouyang DS; Chen Y
PLoS One; 2016; 11(2):e0147183. PubMed ID: 26845774
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo.
He J; Fang P; Zheng X; Wang C; Liu T; Zhang B; Wen J; Xu RA
Drug Des Devel Ther; 2018; 12():513-519. PubMed ID: 29563776
[TBL] [Abstract][Full Text] [Related]
13. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.
Jin Y; Borell H; Gardin A; Ufer M; Huth F; Camenisch G
Eur J Clin Pharmacol; 2018 Apr; 74(4):455-464. PubMed ID: 29273968
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.
Chen SZ; Pan PP; Shen LB; Xu SS; Dai DP; Geng PW; Cai J; Cai JP; Hu GX
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):732-8. PubMed ID: 24986093
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic study of bergamottin-induced inactivation of CYP2C9.
Liu Y; Zhang S; Jiang T; Tan R; Fu Y; Yang X; Gong B; Zou Y; Li W; Zheng J
Food Chem Toxicol; 2021 Jul; 153():112278. PubMed ID: 34019943
[TBL] [Abstract][Full Text] [Related]
16. Effects of methoxychlor and 2,2-bis ( p -hydroxyphenyl)-1,1,1-trichloroethane on cytochrome P450 enzyme activities in human and rat livers.
Chen B; Pan P; Wang L; Chen M; Dong Y; Ge RS; Hu GX
Pharmacology; 2015; 95(3-4):145-53. PubMed ID: 25833162
[TBL] [Abstract][Full Text] [Related]
17. In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction.
Yamaori S; Takami K; Shiozawa A; Sakuyama K; Matsuzawa N; Ohmori S
Biol Pharm Bull; 2015; 38(3):441-7. PubMed ID: 25757926
[TBL] [Abstract][Full Text] [Related]
18. Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats.
He H; Zhang Y; Zhao D; Jiang J; Xie B; Ma L; Liu X; Yu C
Xenobiotica; 2020 Aug; 50(8):939-946. PubMed ID: 32238050
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Interaction Potential between Clopidogrel and Sulfonylurea Antidiabetic Agents: Effects on Clopidogrel Bioactivation.
Shao H; Lu J; Xu YT; Zhan Y; Chen GM; Zhang HJ
Pharmacology; 2016; 97(1-2):18-24. PubMed ID: 26569597
[TBL] [Abstract][Full Text] [Related]
20. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
